B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CPT2

MOLECULAR TARGET

carnitine palmitoyltransferase 2

UniProt: P23786NCBI Gene: 13763 compounds

CPT2 (carnitine palmitoyltransferase 2) is targeted by 3 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CPT2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1perhexiline3.3728
2Lisuride0.691
3Lysergic Acid Diethylamide Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is0.691

About CPT2 as a Drug Target

CPT2 (carnitine palmitoyltransferase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 3 compounds with documented CPT2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CPT2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.